Abstract
Treatment of recurrent or unresectable cutaneous and subcutaneaous tumors continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a palliative treatment of cutaneous and subcutaneous tumor nodules for which standard treatments (e.g. radiotherapy, chemotherapy, and surgery) have failed or proved to be insufficient. ECT combines the electropulsation of tumor cells (by local application of electric pulses) and the administration of antineoplastic drugs such as cisplatin or bleomycin (either intravenous or intratumoral). The permeability of the cancer cells to these poorly permeant anti-tumor drugs is transiently increased up to a hundred-fold. ECT is thus an efficient loco-regional therapy for palliative treatment of unresectable recurrent tumor nodules with overall objective response rates of approximatively 80-90% and has satisfactory cosmetic results. The next challenge for ECT is the treatment of deep-seated tumors and metastases. The joint therapy of ECT and electrotransfer of immune-stimulating genes or electro-photodynamic therapy could be a promising strategy for cancer eradication.
Keywords: Electrochemotherapy, Electropermeabilization, Cisplatin, Bleomycin, clinical trials, subcutaneaous tumors, electrotransfer, immune-stimulating genes, electro-photodynamic therapy, cancer
Current Pharmaceutical Design
Title:Electrochemotherapy: Progress and Prospects
Volume: 18 Issue: 23
Author(s): Jean-Michel Escoffre and Marie-Pierre Rols
Affiliation:
Keywords: Electrochemotherapy, Electropermeabilization, Cisplatin, Bleomycin, clinical trials, subcutaneaous tumors, electrotransfer, immune-stimulating genes, electro-photodynamic therapy, cancer
Abstract: Treatment of recurrent or unresectable cutaneous and subcutaneaous tumors continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a palliative treatment of cutaneous and subcutaneous tumor nodules for which standard treatments (e.g. radiotherapy, chemotherapy, and surgery) have failed or proved to be insufficient. ECT combines the electropulsation of tumor cells (by local application of electric pulses) and the administration of antineoplastic drugs such as cisplatin or bleomycin (either intravenous or intratumoral). The permeability of the cancer cells to these poorly permeant anti-tumor drugs is transiently increased up to a hundred-fold. ECT is thus an efficient loco-regional therapy for palliative treatment of unresectable recurrent tumor nodules with overall objective response rates of approximatively 80-90% and has satisfactory cosmetic results. The next challenge for ECT is the treatment of deep-seated tumors and metastases. The joint therapy of ECT and electrotransfer of immune-stimulating genes or electro-photodynamic therapy could be a promising strategy for cancer eradication.
Export Options
About this article
Cite this article as:
Escoffre Jean-Michel and Rols Marie-Pierre, Electrochemotherapy: Progress and Prospects, Current Pharmaceutical Design 2012; 18 (23) . https://dx.doi.org/10.2174/138161212801227087
DOI https://dx.doi.org/10.2174/138161212801227087 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reversal of Oxidative Stress in Neural Cells by an Injectable Curcumin/Thermosensitive Hydrogel
Current Drug Delivery Recent Developments in Therapeutic Approaches for Lysosomal Storage Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology Navigating the Sea Changes in Patent Law to Successfully Build Value
Technology Transfer and Entrepreneurship (Discontinued) A Review of Recent Patents Concerning Therapy of Respiratory Diseases Using Gene Silencing by RNAi (RISC) and EGS (RNAse P)
Recent Patents on Inflammation & Allergy Drug Discovery Diabetes, Diabetic Complications, and Phosphate Toxicity: A Scoping Review
Current Diabetes Reviews Epidermolysis Bullosa: The Pediatricians Role
Current Pediatric Reviews Endogenous Repair System of Oxidative Damage of DNA
Current Chemical Biology The Therapeutic Potential of Neuro-EPO Administered Nasally on Acute Cerebrovascular Disease
Current Psychopharmacology Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets Polypharmacology of Approved Anticancer Drugs
Current Drug Targets A Guide to Treatment of Sarcoidosis
Current Drug Therapy New Technologies for Drug Delivery Across the Blood Brain Barrier
Current Pharmaceutical Design New Insights into the Diagnosis and Chemotheraphy for Visceral Leishmaniasis
Current Drug Delivery AIDS Related Viruses, their Association with Leukemia, and Raf Signaling
Current HIV Research Characterization and Inhibition of the Recently Discovered Carbonic Anhydrase Isoforms CA XIII, XIV and XV
Current Topics in Medicinal Chemistry Implantable Microfluidic Device: An Epoch of Technology
Current Pharmaceutical Design Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews Gene Delivery System: A Developing Arena of Study for the New Era of Medicine
Recent Patents on DNA & Gene Sequences